Literature DB >> 22795285

The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.

Jason Dungu1, Prayman T Sattianayagam, Carol J Whelan, Simon D J Gibbs, Jennifer H Pinney, Sanjay M Banypersad, Dorota Rowczenio, Janet A Gilbertson, Helen J Lachmann, Ashutosh Wechalekar, Julian D Gillmore, Philip N Hawkins, Lisa J Anderson.   

Abstract

BACKGROUND: About 4% of African Americans possess the isoleucine 122 (V122I) variant of transthyretin, associated with cardiac amyloidosis beyond ages of 55 to 60 years. Transthyretin amyloidosis associated with variant V122I (ATTR V122I) is likely to be an important cause of heart failure in Afro-Caribbean populations, but the high prevalence of left ventricular hypertrophy (LVH) and lack of awareness of this genetic disorder pose diagnostic hurdles. We report the electrocardiographic (ECG) features of ATTR V122I in the largest clinical series to date.
METHODS: Patients with ATTR V122I were identified in collaboration with the UK National Amyloidosis Centre. The ECG at presentation was assessed for cardiac rhythm, axis, and voltage complex size.
RESULTS: We include 64 patients with ATTR V122I, with a median age of 74 years (range, 57-88 years). Normal or increased ECG voltage was present in 44.3% of patients, and overall 25% met the criteria for LVH. A significant negative correlation between voltage complex size and duration of illness was seen (P < .05). First-degree heart block was evident in 56% of patients in sinus rhythm. During follow-up (n = 17; median, 28 months), 50% of patients with initial first-degree heart block required pacing.
CONCLUSION: Electrocardiographic voltages meet the criteria for LVH in one quarter of patients with ATTR V122I cardiac amyloidosis. The widely held belief that cardiac amyloidosis is associated with low-voltage complexes is likely to contribute to underdiagnosis of ATTR V122I. First-degree heart block is common at diagnosis and identifies patients at high risk for subsequent pacing requirement.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795285     DOI: 10.1016/j.ahj.2012.04.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis.

Authors:  Roberta Mussinelli; Francesco Salinaro; Alessio Alogna; Michele Boldrini; Ambra Raimondi; Francesco Musca; Giovanni Palladini; Giampaolo Merlini; Stefano Perlini
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

2.  'Green Apple' Heart Failure.

Authors:  L Oliveira Da Silva; J Fabre; A Monfort; J Villeret; I Citony; P Cohen-Tenoudji; M Lebbadi; D Martin; V Molinié; J Inamo
Journal:  West Indian Med J       Date:  2014-06-25       Impact factor: 0.171

Review 3.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

4.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Authors:  Raymond C Givens; Chris Russo; Philip Green; Mathew S Maurer
Journal:  Aging health       Date:  2013-04-01

Review 5.  Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis.

Authors:  Perryn Lin Fei Ng; Yoke Ching Lim; Lauren Kay Mance Evangelista; Raymond Ching Chiew Wong; Ping Chai; Ching Hui Sia; Hoi Yin Loi; Tiong Cheng Yeo; Weiqin Lin
Journal:  Ann Noninvasive Electrocardiol       Date:  2022-05-14       Impact factor: 1.485

Review 6.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

Review 7.  Epidemiology of the inherited cardiomyopathies.

Authors:  William J McKenna; Daniel P Judge
Journal:  Nat Rev Cardiol       Date:  2020-09-07       Impact factor: 32.419

Review 8.  Cardiac Amyloid - An Update.

Authors:  Jason N Dungu
Journal:  Eur Cardiol       Date:  2015-12

Review 9.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.

Authors:  Joel N Buxbaum; Frederick L Ruberg
Journal:  Genet Med       Date:  2017-01-19       Impact factor: 8.822

Review 10.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.